F10 and atrial fibrillation: A post hoc analysis of the ROCKET AF (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study evaluated outcomes associated with both CV (n = 375 48.2% ECV, 51.8% PCV) and catheter ablation (n = 85) procedures [46] demonstrating that the incidence of embolic events and major or non-major bleeding in the rivaroxaban and warfarin groups were similar.